US-based researchers have proven that 'large' nanoparticles can
pass through human mucus, which means that they could serve as
sustained-release carriers for drugs treating diseases affecting
the mucous membranes, such as...
More effective and easier to administer 'Trojan horse' vaccines
could provide protection for the millions of people at risk from
malaria, TB and AIDS, thanks to a breakthrough from a global
The UK subsidiary of ProMetic Life Sciences has signed a deal with
Novartis to develop a new purification technology for recombinant
protein vaccines that is claimed to be more efficient and cheaper
than currently used methods.
Scientists have discovered an unusual distribution of two proteins
in the lungs and airways of people with cystic fibrosis could form
the basis of a therapy that could better define the immune system's
role in cystic fibrosis.
Qiagen, today announced that it has acquired all outstanding shares
of Genaco Biomedical Products in a deal that adds PCR-based,
multiplexed molecular diagnostics technologies and panels to
BioWa has announced it is to commence Phase 1 clinical trials
anti-IL-5 receptor monoclonal antibody (Mab), which is being
developed for the treatment of asthma, a respiratory disorder that
is on the rise, particularly in children.
Lexicon Genetics has revealed details of the preclinical
development of a novel, orally available small molecule compound
with potential application in the treatment of autoimmune diseases
such as multiple sclerosis and rheumatoid...
Researchers think they have found an explanation as to why
"flesh-eating" bacteria are so resistant to antibiotic treatment,
which could contribute to new strategies for treating necrotizing
fasciitis, halting its rapid...
Wyeth has entered into a global agreement that allows it to use
Intracell's synthetic adjuvant IC31 in the formulation of five of
its investigational vaccines, aiming to simply mix it with antigens
without the need for conjugation.
Chemokine Therapeutics has announced it has received a patent
relating to chemokine analogs for the treatment of human disease,
which includes autoimmune diseases, cancer, cardiovascular disease,
and inflammatory disorders such as...
Researchers believe they have discovered how the HIV virus avoids
the human body's natural defences paving the way for a HIV-specific
cell drug treatment that vastly improves on the drugs that are
AM Pharma has been awarded a US and EU patent for its antimicrobial
peptide to be used in the development of a novel class of drugs
with high efficacy against a broad spectrum of bacterial, fungal
and viral infections.
Researchers have theorised that a peptide found in primates could
halt the HIV-1 virus from infecting blood cells. The discovery
could form the crux of an effective drug therapy, which may
overcome resistance exhibited by current...
A new finding has the potential to pave the way for better
treatment options for autoimmune diseases as researchers discover a
signalling molecule can yield a rapid, inexpensive way to make
large numbers of immune cells.
Predix Phamaceuticals has formed a collaboration with Amgen in a
deal that aims to develop S1P1 modulators for the treatment of
autoimmune diseases. The agreement has the potential to become a
$300m (€235m) payout for Predix.
Momentum is growing at the UK's new National Biomanufacturing
Centre (NBC) as its operator Eden Biodesign inked a second contract
at the centre - set up to establish England's Northwest as one of
the top biomanufacturing...
GlaxoSmithKline (GSK) has asked vaccine developing firm Antigenics
to supply it with more of its QS-21 adjuvant as its vaccines
progress in the pipeline, while at the same the British drug giant
is pushing ahead with its own adjuvant,...
A new computational program has been developed by US researchers
that uses computational systems biology to better understand the
biochemical networks that regulate the interactions between
infectious organisms and the human or animal...
Isotechnika has received an additional US patent for its lead
immunosuppressive drug, which is the first patent to be issued in
this patent family in the US. The lead compound has demonstrated
encouraging results in recent Phase II...
UK biopharma firm Adjuvantix has developed a new technology that it
claims can increase the effectiveness of vaccines as well as drugs
for cancer, inflammatory diseases and infectious diseases such as
tuberculosis and AIDS.
Dynal has announced today the release of a new research tool in its
immunotherapy range that allow researchers to isolate and collect T
cells from immunocompromised patients for ex vivo stimulation and
expansion in a sterile environment.
BioPartners has failed to bring its second biosimilar product into
Europe after the European Agency for the Evaluation of Medicinal
Products (EMEA) issued a negative opinion on its hepatitis C drug,
citing characterisation, manufacturing...
BioPharmaceutical company Protherics, were on hand at the
PiperJaffray conference providing pipeline and company updates to a
audience of investors and analysts. The company are coming off the
back of a successful deal with Astrazeneca...
CureTech has revealed it has wrapped up a deal in which Teva
Pharmaceuticals will invest $6m (€4.7m) in CureTech, for the
development of a revolutionary cancer drug, based on the company's
potential value of $64m.
US biotechnology firm Bio-Bridge Science, whose ambition is to
develop an HIV vaccine, has finished major construction of a good
manufacturing practice (GMP) research and manufacturing facility in
Life sciences firm Cambrex has agreed a contract for the production
of clinical trial quantities of Merrimack Pharmaceuticals'
recombinant immunomodulatory serum protein, as its experience in
the downstream purification of proteins...
Contract biomanufacturing firm Laureate has won a contract to
produce Seattle Genetics' humanised monoclonal antibody product
candidates for clinical trial, adding to its experience in
monoclonal antibody development.
Biophage has completed the final phase of its CRO business
restructuring in preparation to meet the expected demand in
immunotoxicity testing, in which its requirement stems from
increasing legislation that calls for stricter standards.
Vaccine developer Iomai has announced results of a clinical trial
showing its new dry patch formulation for travelers' diarrhea can
trigger a stronger immune response than its wet patch, promising a
vaccine that is easier to...
Biopharmaceuticals manufacturer Cobra will provide process
development and manufacturing of two HIV vaccine candidates for
evaluation in clinical trials under an agreement with the
International AIDS Vaccine Initiative (IAVI) and...